Table 1 Characteristics of the patients
Patient characteristics | Number (%) |
|---|---|
Total patients enrolled | 20 |
 Selinexor 60 mg | 3 |
 Selinexor 80 mg | 17 |
Female | 14 (70%) |
Median age (years, range) | 61 (44–76) |
Disease state on enrollment | |
 Untreated AML | 12 (60%) |
 Relapsed or refractory AMLa | 8 (40%) |
Initial AML diagnosis | |
 De novo AML | 12 (60%) |
 Secondary AML after MDS | 8 (40%) |
European LeukemiaNet genetic risk group | |
 Favorable | 4 (20%) |
 Intermediate I/II | 8 (40%) |
 Adverse | 8 (40%) |
Acquired mutation status | |
 FLT3 | 3 (15%) with ITD, 2 (10%) with TKD mutation |
 CEBPA | 2 (10%) (one had bi-allelic mutation) |
 NPM1 | 5 (25%) (3 with FLT3 mutation) |
Median number of prior regimens (R/R only)a | 2 (range, 1–3) |